Corvus Pharmaceuticals Inc (CRVS) Receives Consensus Rating of “Hold” from Brokerages

Shares of Corvus Pharmaceuticals Inc (NASDAQ:CRVS) have received an average rating of “Hold” from the seven analysts that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $16.00.

CRVS has been the subject of a number of analyst reports. BidaskClub cut shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 21st. Credit Suisse Group raised shares of Corvus Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price objective for the company from $11.00 to $15.00 in a research report on Wednesday, August 15th. Zacks Investment Research raised shares of Corvus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 price objective for the company in a research report on Wednesday, August 8th. Finally, Wedbush reissued an “outperform” rating on shares of Corvus Pharmaceuticals in a research report on Wednesday, August 8th.

A number of large investors have recently bought and sold shares of CRVS. Adams Street Partners LLC lifted its position in shares of Corvus Pharmaceuticals by 21.9% during the first quarter. Adams Street Partners LLC now owns 3,275,616 shares of the company’s stock worth $33,991,000 after purchasing an additional 588,235 shares during the last quarter. Millennium Management LLC lifted its position in shares of Corvus Pharmaceuticals by 925.6% during the first quarter. Millennium Management LLC now owns 605,303 shares of the company’s stock worth $6,979,000 after purchasing an additional 546,286 shares during the last quarter. Cowen Inc. bought a new position in shares of Corvus Pharmaceuticals during the second quarter worth about $5,868,000. BlackRock Inc. lifted its position in shares of Corvus Pharmaceuticals by 51.9% during the second quarter. BlackRock Inc. now owns 1,119,507 shares of the company’s stock worth $12,290,000 after purchasing an additional 382,389 shares during the last quarter. Finally, International Biotechnology Trust PLC bought a new position in shares of Corvus Pharmaceuticals during the second quarter worth about $892,000. 88.72% of the stock is owned by institutional investors.

NASDAQ:CRVS traded down $0.17 on Friday, reaching $7.99. The stock had a trading volume of 61,606 shares, compared to its average volume of 96,544. The stock has a market cap of $251.98 million, a P/E ratio of -3.03 and a beta of -1.74. Corvus Pharmaceuticals has a 12-month low of $6.81 and a 12-month high of $15.64.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its quarterly earnings data on Thursday, August 2nd. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.24. On average, analysts predict that Corvus Pharmaceuticals will post -1.98 earnings per share for the current year.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.

Featured Article: Do You Need a Fiduciary?

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply